FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as   second-line therapy for patients with advanced or metastatic   gastroesophageal adenocarcinoma with or without prior docetaxel: Results   from the phase II RAMIRIS Study of the AIO.

Document type:: Meeting Abstract
Author(s):: Lorenzen, Sylvie; Thuss-Patience, Peter C.; Pauligk, Claudia; Goekkurt, Eray; Ettrich, Thomas Jens; Lordick, Florian; Stahl, Michael; Reichardt, Peter; Soekler, Martin; Pink, Daniel; Probst, Stephan; Hinke, Axel; Goetze, Thorsten Oliver; Al-Batran, Salah-Eddin
Title:: FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel: Results from the phase II RAMIRIS Study of the AIO.
Journal title abbreviation:: J Clin Oncol
Year:: 2020
Journal volume:: 38 Suppl S
Journal issue:: 15
Print-ISSN:: 0732-183X
TUM Institution:: III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
BibTeX

Occurrences: